Your institution may have access to this item. Find your institution then sign in to continue.
Title
A fracture does not adversely affect bone mineral density responses after teriparatide treatment.
Authors
Unnanuntana, Aasis; Ton, Quang V; Kleimeyer, John P; Nguyen, Joseph T; Lane, Joseph M
Abstract
Fracture leads to local and systemic catabolic physiologic changes. As teriparatide is an agent used to treat osteoporosis in patients with fragility fractures, it is unclear whether teriparatide treatment alters bone mineral density (BMD) and bone markers when given to patients with fractures.
Publication
Clinical orthopaedics and related research, 2012, Vol 470, Issue 3, p927